Search Results
Your search for ,loW matches 7101 pages
Showing 2101 - 2150High Prevalence of Previously Undiagnosed Emphysema Among Individuals Undergoing Low-Dose CT Screening for Lung Cancer
In a prospective cohort study reported in Clinical Imaging, David Steiger, MD, of the Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, in New York, and colleagues in the International Early Lung Cancer Action Program (I-ELCAP) identified emphysema in ...
Historic, Present, and Future Perspectives on Breast Cancer in Egypt
Breast cancer is the most frequently diagnosed cancer among women around the world, making it a significant public health problem.1 The disease affects both men and women, although it is rare in men, accounting for just 1% of all breast cancer diagnoses in the United States and less than 0.1% of...
Low-Dose CT Screening for Lung Cancer and the Incidental Findings That May Improve Future Health
Every interaction with patients is an opportunity to change the course of their lives. In the context of screening for disease, every encounter is an opportunity to detect the precursors or early changes that signal early pathophysiology. Smoking status and age are the factors that currently...
Outcomes Notably Improving for Adult ALL
Outcomes in adults with acute lymphoblastic leukemia (ALL) are almost rivaling those in pediatric ALL, thanks to the benefits achieved by incorporating blinatumomab and inotuzumab into chemotherapy regimens. New ways of administering the chemotherapy component are also increasing tolerability and...
Eric Deutsch, MD, PhD, Comments on the Averectal and AVANA Trials in Rectal Cancer
Eric Deutsch, MD, PhD, Professor and Chair of Radiation Oncology at Gustave Roussy, Villejuif, France, commended the speakers for conducting trials whose results he found “very interesting.” The Averectal trial involved a short course of radiation with modified FOLFOX-6 (oxaliplatin, fluorouracil...
Avelumab Under Study as Adjunct to Neoadjuvant Therapy for Rectal Cancer
In the treatment of newly diagnosed locally advanced rectal cancer, two phase II studies evaluating the addition of the PD-L1 inhibitor avelumab to chemoradiotherapy showed promising rates of pathologic complete response, major pathologic response, and tumor downstaging. The study investigators...
Seroconversion After COVID-19 Vaccination in Adult Patients With Hematologic Malignancies
In a single-institution retrospective study reported in a research letter in JAMA Oncology, Ollila et al found a low rate of seroconversion after COVID-19 vaccination among adult patients with hematologic malignancies. Study Details The study included 160 patients at Rhode Island Hospital receiving ...
Outcomes and Behaviors Among Women Receiving or Declining Their Breast Cancer Polygenic Risk Score
A recent study examined patient-reported outcomes and risk-management behaviors of women choosing to receive or decline their breast cancer polygenic risk scores (PRS). The findings were published by Tatiane Yanes, PhD, and colleagues in Genetics in Medicine. The research aimed to look at how the...
Enrollment of AYA Patients Into NCI-Sponsored Clinical Trials: 25-Year Analysis
Adolescent and young adult (AYA) patients with cancer have not seen the same improvements in survival over the years as their pediatric and older adult counterparts. Some evidence has suggested that this may in part be a result of low AYA participation in clinical trials, limiting advances in...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Bahrain
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Bahrain. The aim of this special feature is to highlight the global cancer burden for various countries of the...
Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn for Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
On June 30, 2021, asparaginase erwinia chrysanthemi (recombinant)-rywn was approved as a component of a multiagent chemotherapeutic regimen for treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in adult and pediatric patients 1 month or older who have developed...
JAVELIN Head and Neck 100 Trial: When Failure Seems Fatal, Hope Is Not Lost
Data from KEYNOTE-048 showed that the combination of the checkpoint inhibitor pembrolizumab with platinum-containing therapy improved overall survival vs cetuximab plus chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).1 The findings provided hope...
Salvage and Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: What’s ‘Just Right’ for Our Patients?
In the storied English fable “Goldilocks and the Three Bears,” a child enters a home and tastes three bowls of porridge. She prefers a bowl that is not too cold and not too hot but one that has just the right temperature. This “Goldilocks principle” of “just the right amount” can be applied to the...
Expert Point of View: Thomas Seufferlein, MD, PhD
The invited discussant of APACT,1 Thomas Seufferlein, MD, PhD, Professor of Medicine at the University of Ulm in Germany, said the updated overall survival data “suggest an improved outcome with nab-paclitaxel plus gemcitabine vs gemcitabine alone…. The combination improves long-term survival and...
Facing the Trauma of Colorectal Cancer
I first noticed blood in my stool when I was in the 8th grade. My mom and I did an Internet search and were relieved to find that the cause was most likely nothing more serious than hemorrhoids, so I put the problem out of my mind. I played volleyball and had an active social life, and the...
CAR T-Cell Gene Therapy in Non-Hodgkin Lymphomas
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel gene therapies for resistant non-Hodgkin lymphomas (NHL), including...
A New Era of Hope for Patients With Triple-Negative Breast Cancer
Triple-negative breast cancer is a particularly devastating subtype of breast cancer, as it is often diagnosed in young women and is associated with an exceptionally poor prognosis. The “triple-negative” designation indicates that the three key features driving most breast cancers (estrogen...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Bahrain
The Kingdom of Bahrain is a high-income island nation located in the Persian Gulf. The nation is an archipelago consisting of two separate groups of islands spanning 30 miles north to south, 10 miles east to west, and about 3.5 times the size of Washington, DC. Though situated in a region rich in ...
Cutaneous HPV May Be a Predictor of Cutaneous Squamous Cell Carcinoma Risk
In an article published by Rollison et al in Cancer Research, researchers demonstrated a link between the presence of cutaneous human papillomavirus (HPV) and the incidence of cutaneous squamous cell carcinomas. They also identified key characteristics of infection that may contribute to...
Lung Cancer Screening Rates Improved in 19 States Despite the COVID-19 Pandemic
A new population-based study showed that although national lung cancer screening rates decreased in some states, 19 states actually experienced significant improvements in screening rates despite the COVID-19 pandemic. Overall lung cancer screening rates remained low and unchanged, according to...
An Egyptian Surgical Oncologist Urges Global Cooperation to Achieve Equitable Cancer Care
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Ashraf Zaghloul, MD, DrPH, Professor at the National Cancer Institute of Egypt and President of the Egyptian Society of Surgical Oncology. Dr. Zaghloul was born in 1956 in ...
Revised Children’s Oncology Group Neuroblastoma Risk Classification System
As reported in the Journal of Clinical Oncology by Irwin et al, the Children’s Oncology Group (COG) has developed a new neuroblastoma risk classification (COG version 2) that uses the International Neuroblastoma Risk Group Staging System (INRGSS) and incorporates segmental chromosome aberrations as ...
Expert Point of View: Chris Verslype, MD, PhD
The invited discussant of the RATIONALE 208 trial, Chris Verslype, MD, PhD, Professor of Medicine at University Hospitals Leuven in Belgium, said tislelizumab is an “active and safe” investigational PD-1 antibody, “comparable to other PD-1 agents.” In particular, he noted, the results of RATIONALE ...
Maintaining a Healthy Lifestyle May Decrease Cancer Incidence in High-Risk Individuals
Studies show that unhealthy lifestyles—including smoking, drinking alcohol, having obesity, being physically inactive, and eating a poor diet—are associated with an increased risk of developing cancer. Studies also show that practicing a healthy lifestyle is associated with an increase in total...
Pulsed Vincristine/Dexamethasone Maintenance in Pediatric Acute Lymphoblastic Leukemia
In a Chinese phase III trial (CCCG-ALL-2015) reported in The Lancet Oncology, Yang et al found that 1 year of maintenance therapy with pulsed vincristine and dexamethasone was noninferior to 2 years in low-risk pediatric patients with acute lymphoblastic leukemia and was borderline inferior in...
Impact of Nurse Navigation Program on Outcomes in Minority Patients With Aggressive Lymphoma
In a single-institution study reported in the journal Cancer, Hu et al found that use of a dedicated nurse navigation program contributed to redressing the recognized inequities in care and outcomes between minority patients and White patients with aggressive large B-cell lymphoma (LBCL). As...
Incidence of Axillary Adenopathy in Screening or Diagnostic Mammography After COVID-19 Vaccination
In a single-center retrospective study reported in a research letter in JAMA Oncology, Robinson et al found a vaccine-related axillary adenopathy incidence rate of 3% among women undergoing screening or diagnostic mammography within 90 days of receipt of at least one dose of a COVID-19 vaccine....
Frailty and Neurocognitive Decline Among Young Adult Childhood Cancer Survivors
In a prospective study from the St. Jude Lifetime Cohort reported in the Journal of Clinical Oncology, Williams et al found that prefrailty and frailty among young adult childhood cancer survivors were associated with neurocognitive decline vs nonfrail counterparts, mirroring the association...
Risk of Breast Cancer in Women Older Than Age 65 With Germline Pathogenic Variants in Predisposition Genes
In a study reported in the Journal of Clinical Oncology, Boddicker et al found that women older than age 65 in the general population who carry germline pathogenic variants in established high-risk breast cancer predisposition genes remain at significant risk of late-onset breast cancer and should...
ASTRO Issues New Clinical Guideline on Radiation Therapy for Adult Patients With Soft-Tissue Sarcoma
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) published by Kilian E. Salerno, MD, and colleagues in Practical Radiation Oncology provides guidance on the use of radiation therapy to treat adult patients with soft-tissue sarcomas. Recommendations outline optimal...
Study Explores Rates of Reconstruction for Women With Inflammatory Breast Cancer Undergoing Mastectomy
The percentage of patients with inflammatory breast cancer who select reconstructive surgery after mastectomy—whether immediate or delayed—remains low in spite of improvements in treatment and long-term survival, but the numbers are increasing, according to recent research published by Karadsheh et ...
FDA Alert: Clinical Trial Results Show an Increased Risk of Death Associated With Melphalan Flufenamide
The U.S. Food and Drug Administration (FDA) is alerting patients and health-care professionals that a clinical trial (OCEAN, Study OP-103; ClinicalTrials.gov identifier: NCT03151811) evaluating melphalan flufenamide with dexamethasone to treat patients with multiple myeloma showed an increased risk ...
How Climate Change Is Impacting Cancer Care and What Can Be Done to Reduce Oncology’s Footprint on the Environment
Worldwide, the global average surface temperature has risen at a similar rate of 0.17°F per decade since 1901, with the warmest year on record occurring in 2016 and the second warmest occurring in 2020. However, according to NOAA, since the late 1970s, the United States has warmed faster than the...
Global Estimates of New Cancers Attributable to Alcohol Use in 2020
In a population-based study reported in The Lancet Oncology, Rumgay et al provided estimates of the global incidence of new cancers attributable to alcohol consumption, including the estimate that 4.1% of all new cases in 2020 were related to alcohol use. Study Details In the study, population...
Expert Point of View: Fabrice André, MD, PhD
Fabrice André, MD, PhD, Director of Research and Professor of Medical Oncology at Institut Gustave Roussy, Villejuif, France, commented on the two studies that used the MammaPrint 70-gene signature to identify patients for de-escalation or escalation of endocrine therapy.1,2 The push to...
MINDACT Trial Shows ‘Excellent’ Outcomes in Ultra-Low–Risk Breast Cancer
Patients with ultra-low–risk breast cancer, as classified by the MammaPrint 70-gene assay, had “excellent” long-term outcomes regardless of clinical risk or receipt of adjuvant therapy, a new analysis of the MINDACT trial has shown.1 In a separate study, a retrospective analysis of the National...
Public Comment on National Coverage Analysis of Screening for Lung Cancer With Low-Dose Computed Tomography
The following letter is adapted from comments made to the Centers for Medicare and Medicaid Services (CMS) by the American College of Radiology, the GO2 Foundation for Lung Cancer, and the Society of Thoracic Surgeons. “The American College of Radiology, the GO2 Foundation for Lung Cancer, and the...
Canadian Oncologists Report Costly Delays in Their Drug Regulatory Process
Canada’s publicly funded health-care system has a complex drug approval and funding process. Due to multiple assessment steps and bureaucratic processes, newly developed cancer drugs can often experience long delays before oncologists may use them to treat their patients with cancer. Several...
Early-Phase Trial Finds Mirvetuximab Soravtansine Plus Bevacizumab Active in Recurrent Ovarian Cancer
In patients with recurrent ovarian cancer, the antibody-drug conjugate mirvetuximab soravtansine, given with bevacizumab, showed antitumor activity leading to durable responses in platinum-agnostic patients with strong expression of folate receptor alpha (FRα), researchers reported at the 2021 ASCO ...
Bringing Palliative Care to Native American Patients With Cancer
Native Americans are among the most underserved minority populations in the United States and are disproportionately affected by cancer. They have the lowest survival rates for nearly all types of cancer of any minority population and much higher rates of certain types of cancer, including lung,...
Role of PI3K Inhibition in Indolent Lymphomas
As reported by Fowler et al in the Journal of Clinical Oncology1—and summarized in this issue of The ASCO Post—the international phase IIb UNITY-NHL trial of 208 patients with marginal zone lymphoma (MZL; n = 69), follicular lymphoma (FL; n = 117), and small lymphocytic lymphoma (SLL; n = 22)...
Dual PI3Kδ/CK1ε Inhibitor Umbralisib in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
As reported in the Journal of Clinical Oncology by Nathan H. Fowler, MD, of The University of Texas MD Anderson Cancer Center, and colleagues, a phase IIb trial (UNITY-NHL) has shown that the dual PI3Kδ/casein kinase (CK)1ε inhibitor umbralisib produced durable responses in patients with relapsed...
Nomograms for Predicting Outcomes With LuPSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
In a retrospective study reported in The Lancet Oncology, Gafita et al developed nomograms for predicting overall survival and prostate-specific antigen (PSA) progression-free survival outcomes in men receiving lutetium-177–PSMA (LuPSMA) treatment for metastatic castration-resistant prostate...
Outcomes in Patients With HER2-Low–Positive Breast Cancer Participating in Neoadjuvant Clinical Trials
In a pooled analysis of individual patient data from breast cancer neoadjuvant clinical trials reported in The Lancet Oncology, Carsten Denkert, MD, and colleagues found that pathologic complete response and survival rates for patients with HER2-low–positive vs HER2-zero tumors differed according...
Ruxolitinib for Glucocorticoid-Refractory or -Dependent Chronic Graft-vs-Host Disease After Allogeneic Stem Cell Transplantation
In the phase III REACH3 trial, reported in The New England Journal of Medicine, Robert Zeiser, MD, and colleagues found that ruxolitinib produced a significantly higher overall response rate vs investigator-selected control treatments in patients with glucocorticoid-refractory or -dependent chronic ...
Is There a Disease-Free Survival Benefit With Adjuvant Celecoxib in HER2-Negative Breast Cancer?
In the phase III REACT trial reported in JAMA Oncology, R. Charles Coombes, MD, PhD, and colleagues found no disease-free survival benefit with the addition of 2 years of adjuvant celecoxib vs placebo to conventional adjuvant treatment in patients with HER2-negative breast cancer. Study Details...
Interleukin-2 Pathway Agonist Bempegaldesleukin Plus Nivolumab in the First-Line Treatment of Metastatic Melanoma
In the phase II cohort of a phase I/II trial (PIVOT-02) reported in the Journal of Clinical Oncology, Adi Diab, MD, and colleagues found that the combination of the interleukin-2 pathway agonist bempegaldesleukin and nivolumab produced high response rates and extended progression-free survival in...
Pregnancy Outcomes and Maternal Complications Among Survivors of Breast Cancer
In a systematic review and meta-analysis reported in the Journal of Clinical Oncology, Matteo Lambertini, MD, PhD, and colleagues found that breast cancer survivors were less likely to have subsequent pregnancy vs the general population and more likely to have preterm birth. However, no reduction...
Low-Volume Recurrent Metastatic Castration-Sensitive Prostate Cancer
In this video, Drs. Matthew R. Smith, Xin Gao, and Alicia K. Morgans discuss the management of metastatic castration-sensitive prostate cancer, focusing on data from the phase III TITAN trial. The faculty present the case of a 73-year-old man with recurrent, low-volume/low-risk metastatic...
Consensus Statement From IASLC on Liquid Biopsy for Advanced NSCLC
As reported in the Journal of Thoracic Oncology by Christian Rolfo, MD, PhD, and colleagues, the International Association for the Study of Lung Cancer (IASLC) has issued a consensus statement on the use of liquid biopsy in advanced non–small cell lung cancer (NSCLC). Select recommendations are...
